The historical data trend for Eli Lilly and Co's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Eli Lilly and Co Annual Data
Trend
2015-12
2016-12
2017-12
2018-12
2019-12
2020-12
2021-12
2022-12
2023-12
2024-04
Forward PE Ratio
22.68
17.95
18.15
19.16
19.65
20.88
32.05
44.05
47.62
60.24
Eli Lilly and Co Quarterly Data
2015-12
2016-03
2016-06
2016-09
2016-12
2017-03
2017-06
2017-09
2017-12
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
Forward PE Ratio
22.68
18.02
20.96
19.53
17.95
20.45
19.92
18.83
18.15
15.95
16.56
18.83
19.16
22.88
19.72
17.04
19.65
19.80
24.27
19.01
20.88
22.62
29.41
26.39
32.05
33.90
39.22
34.36
44.05
40.00
53.76
42.19
47.62
62.11
Competitive Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co Forward PE Ratio Distribution
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's Forward PE Ratio falls into.
Eli Lilly and Co Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Eli Lilly and Co (NYSE:LLY) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Eli Lilly and Co Forward PE Ratio Related Terms
Thank you for viewing the detailed overview of Eli Lilly and Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Eli Lilly and Co (Eli Lilly and Co) Business Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LLY has been successfully added to your